Stock AGEN AGENUS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Agenus Inc.

Equities

AGEN

US00847G8042

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
15.25 USD +11.97% Intraday chart for Agenus Inc. +37.14% -7.90%
May. 16 Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer CI
May. 07 Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
BU
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
BU
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
BU
Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading
MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates
MT
Transcript : Agenus Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M
MT
Agenus: Q1 Earnings Snapshot
AQ
Agenus Reports First Quarter 2024 Results
BU
Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus? Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program
CI
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
BU
Agenus Inc. - Botensilimab, Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
AQ
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
BU
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
BU
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
AQ
Sector Update: Health Care Stocks Slipping Late Afternoon
MT
Sector Update: Health Care
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AGEN Stock
  4. News Agenus Inc.